SRPTSarepta Therapeutics, Inc.
Price
+2.4%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality strong, hard red flags, undemanding price, growth fading, the market against it.
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne muscular dystrophy ("Duchenne") and are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne and LGMD.
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Sarepta Therapeutics, Inc. (SRPT) reported revenue of $401M in Q2 2026 (quarter ended Jun 30, 2026), down 34% from the same quarter a year earlier. That came with net loss of $4.9M. For the full year FY2025, revenue was $2.20B (+16% year on year) and net income −$713M. Its largest region in Q2 2026 was United States at $199M, 86% of the disclosed total, well ahead of Non Us at 14%. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 23, 2026On September 23, 2026 (the “Effective Date”), Sarepta Therapeutics, Inc. (the “Company”), Sarepta Therapeutics Three, LLC (“Sarepta Three” and, together with the Company, “Sarepta”), REGENXBIO Inc. (“REGENXBIO”), the Trustees of the University of Pennsylvania (“UPenn”) and Catalent, Inc. (“Catalent”) entered into a …Material agreement entered · Form 8-K
- Aug 5, 2026Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments.Earnings release · press release
- Jul 27, 2026On July 23, 2026, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the “Company”) appointed Michael Severino, M.D. as Chief Executive Officer of the Company, effective July 28, 2026 (the “Effective Date”)Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $230.6MThe company’s own SEC segment disclosure.
- United States$198.6M86%
- Non Us$32.0M14%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.